Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD) has been a major challenge in the field of public health worldwide because of its high morbidity and mortality rates. In 2012, more than 3 million people worldwide died of this disease and its complications, and it is expected to be the third leading cause of death by 2030.[@CIT0001] COPD cannot be cured, as a chronic progressive disease, but it can be controlled at a relatively stable stage after effective treatment.[@CIT0002] However, most patients with COPD cannot control the progress of the disease effectively. One of the key reasons for this is that patients face many medication-related problems, including low medication adherence rates,[@CIT0003],[@CIT0004] inability to use inhaler devices correctly,[@CIT0005] and failure to take medication properly.[@CIT0006] The medication-related issues that COPD patients face and the consistent care that they need to manage their chronic conditions highlight the importance of the professional role of pharmacists.[@CIT0007]

The responsibility of the pharmacist is no longer simple drug-adjustment work, but has been expanded to become patient-centric diversified health management.[@CIT0008],[@CIT0009] The situation is particularly prominent in COPD, in which the roles of pharmacist had been expanded to encompass prevention, screening potential patients, disease counselling, comprehensive disease management, and education.[@CIT0010]--[@CIT0012] Studies have demonstrated that COPD patients benefit from multifactorial intervention by clinical pharmacists, including improvement of their COPD knowledge, medication adherence, and quality of life; and decreases in the hospitalization rate and exacerbations.[@CIT0013],[@CIT0014] However, a thorough understanding of the role of community pharmacists in COPD management is comparatively scarce.

Being positioned as the first point of contact with the healthcare service and medical experts, community pharmacists are uniquely placed to help manage each stage of COPD.[@CIT0015]--[@CIT0018] However, the components of professional services provided by community pharmacists for COPD patients, health-related outcomes from community pharmacist interventions, and the impact of contextual factors vary in the existing literature.[@CIT0019] There is a need to comprehensively review and summarize community pharmacists' contribution to COPD management into a theoretical structure to guide the planning and implementation of community pharmacist's' professional services for COPD patients in community settings.

Thus, the aim of this research was to identify and analyse the professional services provided by community pharmacists for patients with COPD, the outcomes of such services, and contextual factors affecting the practice, using a systematic literature review guided by the logic modelling approach. It is expected that the findings could help to guide the future development and implementation of professional services of community pharmacists in COPD management.

Methods {#S0002}
=======

Search Strategy {#S0002-S2001}
---------------

This systematic review was performed according to the PRISMA guidelines for searching the literature. The literature search was conducted in June 2019. Articles published from January 2009 to June 2019 were included.

Four English-language databases (PubMed, Web of Science, Embase, and Scopus) and one Chinese database (CNKI) were searched for peer-reviewed research published between January 2009 and June 2019. The three primary search terms were "pharmacy or pharmacist", "COPD", and "professional service". As shown in [Table 1](#T0001){ref-type="table"}, the operational definition used for these three primary terms referred to "pharmacy or pharmacist" as the location or provider of COPD management intervention, "COPD" as COPD-related vocabularies, and "professional service" as the intervention provided associated with COPD management. MeSH terms and keywords were used to develop a comprehensive search strategy and to ensure the validity of the strategy. Terms within "pharmacy or pharmacist", "COPD", and "professional service" were combined with OR, and the following results from each concept were combined with AND. In addition, reference lists and citations of the included studies in this review were examined in an attempt to identify additional papers relevant for inclusion. For the Chinese literature, the search strategy was translated into Chinese and employed in a similar manner.Table 1Search Term IdentifiersCategoryEntry Search TermsPharmac\*Pharmacist\*PharmacyPharmaciesCOPDChronic Obstructive Pulmonary DiseaseCOPDChronic Airflow ObstructionBronchialRespiratoryAirwayProfessional servicePharmaceutical ServicePharmaceutical CareMedicationPrescriptionSpirometerBronchodilatorDrug\*Medicine\*Inhal\*[^1]

Inclusion and Exclusion Criteria {#S0002-S2002}
--------------------------------

For study selection, the following inclusion criteria were used: 1) community pharmacists should be the main intervention providers; 2) the main target disease is COPD; 3) it must include specific services or interventions provided by community pharmacists; and 4) it should be original research, but with no limits on research methods. Exclusion criteria included: 1) the main location for implementation was a hospital; 2) research was specific to a certain drug; and 3) review articles.

Study Selection Procedure {#S0002-S2003}
-------------------------

[Figure 1](#F0001){ref-type="fig"} presents the whole study selection procedure. First, we acquired 9971 articles from the English literature and 263 from the Chinese literature. Second, we excluded the duplicated literature and obtained 6391 independent records. Third, we screened the remaining records by applying the inclusion criteria mentioned in the previous subsection, and obtained 32 records that potentially met the requirements. Fourth, we excluded 10 of the records after full-text reading. Fifth, we included another 3 papers from the references of the selected articles.Figure 1Study selection procedure.

This screening process was completed by two authors (YH and DY) independently. When there was a conflict between the two authors' opinions, the selected literature was further discussed, and another researcher (COLU) participated in the ruling to jointly determine the final included literature. In the end, no Chinese literature met the selection criteria, and 25 English literature articles were used for the final analysis.

Data Extraction and Analysis {#S0002-S2004}
----------------------------

Data were extracted using four extraction tables ([Tables 2](#T0002){ref-type="table"}[](#T0003){ref-type="table"}[](#T0004){ref-type="table"}[](#T0005){ref-type="table"}--[6](#T0006){ref-type="table"}), where the basic information on the article, intervention from pharmacists, outputs, outcomes, and contextual factors were compiled and extracted.Table 2Summary of Basic Information of Selected ArticlesAuthors (Publication Year)LocationDesignQualityParticipantsCastillo et al (2009)[@CIT0024]SpainCross-sectional study63% (5/8)161 patientsMehuys et al (2010)[@CIT0025]BelgiumCross-sectional study75% (6/8)93 pharmacy, 555 patientsHammerlein et al (2011)[@CIT0026]GermanyNon-randomized controlled trial78% (7/9)757 patientsVerma et al (2012)[@CIT0027]UKCross-sectional study50% (4/8)2273 pharmacistsBeauchesne et al (2012)[@CIT0028]CanadaCase series40% (4/10)141 patientsPetkova et al (2012)[@CIT0029]BulgariaRandomized controlled trial77% (10/13)26 patients total (13 for intervention group, 13 for control group)Fuller et al (2012)[@CIT0030]USANon-randomized controlled trial89% (8/9)185 patientsTakemura et al (2013)[@CIT0031]JapanNon-randomized controlled trial78% (7/9)170 patientsTommelein et al (2014)[@CIT0032]BelgiumRandomized controlled trial85% (11/13)734 patients total (371 for intervention group, 363 for control group)Tommelein et al (2014)[@CIT0033]BelgiumCross-sectional study88% (7/8)80 pharmacistsOttenbros et al (2014)[@CIT0034]NetherlandsCohort study91% (10/11)3757 patientsCastillo et al (2015)[@CIT0035]SpainCross-sectional study100% (8/8)100 pharmacies, 3121 patientsWright et al (2015)[@CIT0036]UKNon-randomized controlled trial89% (8/9)360 patientsBouwmeester et al (2015)[@CIT0037]UKCase Series90% (9/10)42 patientsApikoglu-Rabus et al (2016)[@CIT0038]TurkeyNon-randomized controlled trial67%(6/9)109 patientsDavis et al (2016)[@CIT0039]CanadaStudy protocol for randomized controlled trial77% (10/13)--Fathima et al (2017)[@CIT0040]AustraliaCross-sectional study (main) and non-randomized controlled trial (minor)75% (6/8)20 pharmacists, 167 patientsDetoni et al (2017)[@CIT0041]BrazilNon-randomized controlled trial89% (8/9)83 patientsCastel-Branco et al (2017)[@CIT0042]PortugalCross-sectional study88% (7/8)67 patientsHeikkila et al (2018)[@CIT0043]FinlandCross-sectional study100% (8/8)741 pharmacistsRuud et al (2018)[@CIT0044]NorwayNon-randomized controlled trial56% (5/9)405 patientsAlton et al (2018)[@CIT0045]UKNon-randomized controlled trial78% (7/9)54 patientsKlassing et al (2018)[@CIT0046]USARandomized controlled trial77% (10/13)831 patients total (276 for phone call group, 277 for letter group, 278 for control group)Fathima et al (2019)[@CIT0047]AustraliaCross-sectional study75% (6/8)35 pharmacistsHesso et al (2019)[@CIT0048]UKSemi-structured interviews90% (9/10)23 pharmacists Table 3Interventions Conducted by PharmacistsIntervention CategoryIntervention ItemsA Primary preventionA1 Smoking cessation[@CIT0024],[@CIT0025],[@CIT0027]-[@CIT0030],[@CIT0032],[@CIT0033],[@CIT0035],[@CIT0036],[@CIT0038],[@CIT0039],[@CIT0043],[@CIT0045],[@CIT0048]A2 Lifestyle advice[@CIT0036],[@CIT0038],[@CIT0043]B Early detectionB1 Assess patient risk and health status[@CIT0024],[@CIT0035],[@CIT0036],[@CIT0040],[@CIT0041]B2 Self-diagnosis questionnaire[@CIT0024],[@CIT0025],[@CIT0030],[@CIT0035],[@CIT0036],[@CIT0045],[@CIT0047]B3 Spirometry testing[@CIT0024],[@CIT0030],[@CIT0035],[@CIT0040],[@CIT0047]B4 Referral/recommend high-risk customer to doctor[@CIT0024],[@CIT0030],[@CIT0035],[@CIT0036],[@CIT0040],[@CIT0043],[@CIT0047]C Therapy managementC1 General service in pharmacy[@CIT0025],[@CIT0027]-[@CIT0029],[@CIT0031]--[@CIT0034],[@CIT0036],[@CIT0038],[@CIT0039],[@CIT0041],[@CIT0043],[@CIT0045],[@CIT0048]C1.1 Dispensing[@CIT0025],[@CIT0029],[@CIT0034],[@CIT0038],[@CIT0043],[@CIT0048]C1.2 Notification of frequency and dose[@CIT0027]--[@CIT0029],[@CIT0031]--[@CIT0034],[@CIT0036],[@CIT0038],[@CIT0039],[@CIT0041],[@CIT0043],[@CIT0045],[@CIT0048]C1.3 Notification of adherence[@CIT0027],[@CIT0028],[@CIT0031]-[@CIT0034],[@CIT0038],[@CIT0039],[@CIT0041],[@CIT0043],[@CIT0045],[@CIT0048]C1.4 Notification of drug interactions[@CIT0027],[@CIT0028],[@CIT0032],[@CIT0034],[@CIT0038],[@CIT0041],[@CIT0043],[@CIT0045]C1.5 Notification of adverse drug reactions[@CIT0027]--[@CIT0029],[@CIT0032]--[@CIT0034],[@CIT0038],[@CIT0041],[@CIT0043],[@CIT0045]C1.6 Long-term monitoring of adverse drug reactions[@CIT0033],[@CIT0043]C2 Introduction of pathological information[@CIT0031]--[@CIT0033]C3 Assessing stage of disease[@CIT0035],[@CIT0038],[@CIT0039],[@CIT0043]C4 Inhalation technique education[@CIT0025],[@CIT0026],[@CIT0028],[@CIT0029],[@CIT0031]-[@CIT0034],[@CIT0036]--[@CIT0039],[@CIT0042]--[@CIT0045]C4.1 Inhalation technique short-term instruction[@CIT0025],[@CIT0026],[@CIT0028],[@CIT0029],[@CIT0031]-[@CIT0034],[@CIT0036]--[@CIT0039],[@CIT0042]--[@CIT0045]C4.2 Inhalation technique long-term check[@CIT0031]--[@CIT0033],[@CIT0043]--[@CIT0045]D Long-term health managementD1 Long-term follow-up and consultation[@CIT0029],[@CIT0032],[@CIT0033],[@CIT0036],[@CIT0038],[@CIT0043],[@CIT0045]D2 Prevention and treatment of exacerbations[@CIT0029],[@CIT0031]-[@CIT0033],[@CIT0036],[@CIT0038],[@CIT0039],[@CIT0043]D3 Influenza vaccination reminder[@CIT0025],[@CIT0032],[@CIT0033],[@CIT0043],[@CIT0046],[@CIT0048]D4 Self-care management support[@CIT0032],[@CIT0033]D5 Integrated care with other healthcare provider[@CIT0032],[@CIT0039] Table 4Outputs of Pharmacist InterventionOutputsMedication adherence (+)[@CIT0032]--[@CIT0034],[@CIT0036],[@CIT0038],[@CIT0041]Medicines/treatment optimization (+)[@CIT0034],[@CIT0045]Inhalation technique (+)[@CIT0026],[@CIT0029],[@CIT0031]-[@CIT0034],[@CIT0037],[@CIT0042],[@CIT0044],[@CIT0045],[@CIT0047]Influenza vaccination injection rate[@CIT0025],[@CIT0046]Smoking cessation (+),[@CIT0027],[@CIT0030],[@CIT0036],[@CIT0038] (=)[@CIT0033]Identify probable underdiagnosed patients[@CIT0024],[@CIT0030],[@CIT0035],[@CIT0040],[@CIT0047]Information obtained (+)[@CIT0029][^2] Table 5Outcomes of Pharmacist InterventionOutcomesClinical outcomesHealth status (+),[@CIT0041],[@CIT0045] (=)[@CIT0031],[@CIT0033]Quality of life (+)[@CIT0029],[@CIT0036]Frequency of exacerbations (--)[@CIT0029],[@CIT0031],[@CIT0033]COPD-related symptom (--)[@CIT0029],[@CIT0036],[@CIT0038],[@CIT0041]Hospitalization rate (--)[@CIT0029],[@CIT0032]Severity of exacerbations (=)[@CIT0033]Humanistic outcomesSatisfaction with pharmacy services (+)[@CIT0029],[@CIT0047]Economic outcomesOverall healthcare costs (--)[@CIT0036][^3] Table 6Contextual Factors for Pharmacist InterventionResourcesContextual FactorsPharmacistsLack of time[@CIT0028],[@CIT0033],[@CIT0048]Workload[@CIT0048]Insufficient knowledge about medications[@CIT0033],[@CIT0048]Lack of remuneration[@CIT0033]Administrative burden experienced by pharmacists[@CIT0033]Other healthcare providersIntegration with service from other healthcare provider[@CIT0026],[@CIT0035],[@CIT0040],[@CIT0045],[@CIT0047],[@CIT0048]Communication[@CIT0048]PatientsWillingness to pay for the service[@CIT0030]Cognitive function for elderly patients[@CIT0037]Lack of COPD awareness and attitude[@CIT0047],[@CIT0048]Lack of time[@CIT0048]FacilitiesSoftware support[@CIT0032],[@CIT0040]Clinic contextsExact evidence with healthcare saving[@CIT0034]Socio-economic factorsFinancial reward[@CIT0030],[@CIT0033],[@CIT0036],[@CIT0047],[@CIT0048]

For professional services, we integrated the models of the International Pharmaceutical Federation (FIP)[@CIT0010] and van der Molen,[@CIT0018] which specified the definition of services for COPD provided by community pharmacists. The services were classified into four categories according to the previous research: 1) primary prevention: pharmacists are ideally placed to provide information on disease awareness and risk prevention campaigns; 2) early detection: pharmacists play an important role in the early identification of patients with COPD; 3) therapy management: pharmacists can assist patients on drug-related issues during treatment; and 4) long-term health management: pharmacists play a role in monitoring adherence and ongoing inhaler technique in patients with COPD.[@CIT0018] For output and outcome, the Economic, Clinical, and Humanistic Outcomes (ECHO) model was used to summarize the economic, clinical, and humanistic outputs and outcomes.[@CIT0019] All of the outputs and outcomes about COPD have been confirmed in previous research.[@CIT0021],[@CIT0022]

Study Appraisal {#S0002-S2005}
---------------

Considering the diversity of the study types included in this review, the Critical Appraisal Tools developed by the Joanna Briggs Institute (JBI) were applied as an evaluation tool to critically assess the methodological quality and risk of bias.[@CIT0023] The JBI tools, which evaluate the risk of bias from different aspects, include checklists of 6--13 questions, depending on the type of research methodology. There are four options for the assessment answers to each items on the JBI checklists: "Yes", "No", "Unclear", and "Not applicable". For the purpose of this study, we considered the option "Unclear" as equivalent to the option "No", while the option "Not applicable" was considered equivalent to the option "Yes". For the convenience of normalizing the calculation of the overall score for each study, either "Unclear" or "No" in the response would score 0 points for that specific item, while "Not applicable" or "Yes" would score 1 point.

Two authors (YH and DY) evaluated each article independently, based on the JBI tool. If there was a conflict in the evaluation result between the two authors' opinions, an independent third researcher (COLU) participated in the evaluation process and made the final decision. The quality of all studies was classified as good quality, fair quality, or poor quality based on the degree to which they satisfied the checklists. Research was considered good quality if the study met all items on the checklist; a study was considered fair quality if it satisfied 70% or more of total items; and a study was considered poor quality if the it satisfied less than 70% of all the items on the corresponding checklists.

Results {#S0003}
=======

Included Studies {#S0003-S2001}
----------------

As shown in [Table 2](#T0002){ref-type="table"}, 25 studies published in English met the criteria and were included in the systematic review. With regard to the method of the article, 13 (52%) of the literature results were observational studies, including 9 cross-sectional studies, 2 case series, 1 cohort study, and 1 interview research; 10 (40%) of them were experimental studies, including 7 non-randomized controlled trials, 3 randomized controlled trials (RCTs), 1 study protocol for an RCT and 1 study that used cross-sectional research and an RCT in a mixed method. Fifteen countries were involved in the studies, with the most common study locations including the UK (n=5), Belgium (n=3), Australia (n=2), Canada (n=2), Spain (n=2), and the USA (n=2). The included studies involved both patient and pharmacist as participants, in which patients alone were involved in 17 of the included studies (68%), pharmacists alone were involved in 6 studies (24%), and both patients and pharmacists were involved in 2 studies (8%).

Study Quality {#S0003-S2002}
-------------

Among the 25 included studies, 2 cross-sectional studies[@CIT0026],[@CIT0034] were deemed to have good quality, having full compliance to the corresponding checklist; 18 studies were considered as having fair quality, as most of them were found to have non-compliance to at least 2 items on the corresponding checklists. Major methodological flaws were noted in 5 studies (comprising 2 cross-sectional studies, 2 non-randomized control studies, and 1 case series), which were evaluated as having poor quality (see [[Supplementary material 1](https://www.dovepress.com/get_supplementary_file.php?f=254477.xlsx)]{.ul}). Despite the variations in the study quality, considering the purpose of this study, which was to provide a broad overview of the current understanding about community pharmacists' role in COPD management (including the contextual factors, types of interventions, and possible output and outcomes) but not to evaluate the effectiveness of the interventions, all of the studies were included for further analysis.

Professional Services {#S0003-S2003}
---------------------

### Primary Prevention {#S0003-S2003-S3001}

Primary prevention was suggested as a role for community pharmacist practice. Regarding the responsibility of pharmacists, on the one hand, the pharmacist should provide health education for potentially high-risk patients and encourage people, especially those who show airway obstruction and a history of lung disease, to cease smoking.[@CIT0024],[@CIT0035],[@CIT0036] On the other hand, for patients already diagnosed with COPD, the pharmacist needs to ask them whether they smoke, inform them about the risks of smoking, and encourage them to quit .[@CIT0025],[@CIT0027]-[@CIT0030],[@CIT0032],[@CIT0033],[@CIT0038],[@CIT0039],[@CIT0043],[@CIT0045],[@CIT0048] Other high-risk factors, such as diet and nutrition,[@CIT0036],[@CIT0043] weight control,[@CIT0036],[@CIT0043] drinking,[@CIT0036] and other lifestyle changes that reduce the incidence and progression of diseases, have also been mentioned.

### Early Detection {#S0003-S2003-S3002}

The convenience of contact between pharmacists and patients and the professionalism of pharmacists[@CIT0008],[@CIT0018],[@CIT0030] provide pharmacists with the advantage of being able to identify potential COPD patients in high-risk groups and to allow them to receive effective treatment as early as possible to control the further development of the disease. Pharmacists could observe the patient's health status, whether the patient showed symptoms of airway obstruction,[@CIT0024] had a history of lung disease over the age of 40,[@CIT0035] purchased drugs for COPD but had not been diagnosed,[@CIT0036] and had a history of smoking over the age of 35.[@CIT0040],[@CIT0047] For those at high risk of COPD, patients were provided with self-filled questionnaires for self-diagnosis and self-evaluation. Questionnaires provided for patients included the GOLD screening questionnaire,[@CIT0024],[@CIT0030],[@CIT0035] St. George's Respiratory Questionnaire (SGRQ),[@CIT0025] COPD Assessment Test (CAT),[@CIT0036],[@CIT0045] and Initial Screening Questionnaire (ISQ),[@CIT0040],[@CIT0047] four different kinds of questionnaire but all used to assess the risk of COPD and the extent of disease progression. For patients whose questionnaire scores reach a certain level, it is recommended that they undergo lung function tests (LFTs) to further evaluate the risk of COPD disease. Patients with higher risks are referred to a physician for further treatment, according to the test results.[@CIT0024],[@CIT0030],[@CIT0035],[@CIT0040],[@CIT0047] For all this, there may be some uncertainty in the questionnaire and LFTs, so it is necessary, according to the judgement of the pharmacist, to recommend seeking further medical treatment, even if the patients who are tested are at low risk.[@CIT0048]

### Therapy Management {#S0003-S2003-S3003}

The management of patients' therapy by pharmacists can be divided into two levels. On the first level, pharmacists provided non-specific pharmacy services,[@CIT0025],[@CIT0027]-[@CIT0029],[@CIT0031]--[@CIT0034],[@CIT0036],[@CIT0038],[@CIT0039],[@CIT0041],[@CIT0043],[@CIT0045],[@CIT0048] such as dispensing;[@CIT0025],[@CIT0029],[@CIT0034],[@CIT0038],[@CIT0043],[@CIT0048] counselling on medicine administration dose and frequency,[@CIT0027]--[@CIT0029],[@CIT0031]--[@CIT0034],[@CIT0037]--[@CIT0039],[@CIT0041],[@CIT0043],[@CIT0045],[@CIT0048] adherence,[@CIT0027],[@CIT0028],[@CIT0031]-[@CIT0034],[@CIT0038],[@CIT0039],[@CIT0041],[@CIT0043],[@CIT0045],[@CIT0048] drug interactions,[@CIT0027],[@CIT0028],[@CIT0032],[@CIT0034],[@CIT0038],[@CIT0041],[@CIT0043],[@CIT0045] and adverse drug reactions,[@CIT0027]--[@CIT0029],[@CIT0032]--[@CIT0034],[@CIT0038],[@CIT0041],[@CIT0043],[@CIT0045] as well as long-term monitoring of adverse drug reactions.[@CIT0033],[@CIT0043] On the second level, owing to the particular characteristics of the medication and management of COPD, there were other pharmacy practices that community pharmacists could provide specifically for COPD patients, such as the introduction of pathological information[@CIT0031]--[@CIT0033] and assessing the stage of disease.[@CIT0035],[@CIT0038],[@CIT0039],[@CIT0043] At the same time, as the current mainstay of treatment for COPD, inhaled medication therapy needed more education from pharmacists, leading to improved inhalation techniques.[@CIT0012],[@CIT0049] To achieve the goal of optimizing the inhalation technique, pharmacists' education for patients needs to include both short-term instruction, in which pharmacists teach patients how to correctly use the inhalation device until the patients demonstrate understanding and proper handling techniques;[@CIT0025],[@CIT0026],[@CIT0028],[@CIT0029],[@CIT0031]-[@CIT0034],[@CIT0036]--[@CIT0039],[@CIT0042]--[@CIT0045] and long-term using monitor levels, in which patients are required to demonstrate using the device while the pharmacist evaluates them and then, if necessary, corrects their use in the subsequent process.[@CIT0031]--[@CIT0033],[@CIT0043]--[@CIT0045]

### Long-Term Health Management {#S0003-S2003-S3004}

Based on the basic short-term treatment, pharmacists will further monitor the patients as long-term health management. The main intervention measures were worsening risk monitoring[@CIT0029],[@CIT0031]-[@CIT0033],[@CIT0036],[@CIT0038],[@CIT0039],[@CIT0043] and long-term patient follow-up and counselling services,[@CIT0029],[@CIT0032],[@CIT0033],[@CIT0036],[@CIT0038],[@CIT0043],[@CIT0045] which aimed to check the compliance of patients with medication and the progress of COPD, and to provide professional guidance to patients at any time when they needed it.

At the same time, pharmacists helped COPD patients to enhance their self-management of the disease,[@CIT0032],[@CIT0033] assisted in establishing a lifestyle in which patients could manage themselves, and actively cooperated with other medical service providers, such as physicians[@CIT0032],[@CIT0045] and nurses;[@CIT0039] all in all, they provided patients with long-term and comprehensive supervision services. In addition, pharmacists would recommend that patients with COPD, especially those over 65 years of age,[@CIT0025] received an influenza vaccine during the flu-prone season to reduce the risk of acute exacerbation of COPD.[@CIT0025],[@CIT0032],[@CIT0033],[@CIT0043],[@CIT0046],[@CIT0048]

Outputs {#S0003-S2004}
-------

Among all of the outputs, the most popular output referred to in the studies was the patients' technique in using inhalation devices, and all studies showed positive intervention effects (n=11).[@CIT0026],[@CIT0029],[@CIT0031]-[@CIT0034],[@CIT0037],[@CIT0042],[@CIT0044],[@CIT0045],[@CIT0047] This was followed by medication compliance; all studies involving compliance showed that patient compliance improved after intervention by a pharmacist.[@CIT0032]--[@CIT0034],[@CIT0036],[@CIT0038],[@CIT0041] Of the studies involving interventions for patients to quit smoking, most (n=4) showed a positive effect;[@CIT0027],[@CIT0030],[@CIT0036],[@CIT0038] however, Tommelein et al reported there was no help available for the intervention. The literature also supported pharmacists' ability to assist in identifying high-risk patients with COPD from the population after professional training.[@CIT0024],[@CIT0030],[@CIT0035],[@CIT0040],[@CIT0047] Two studies on influenza vaccination for COPD patients showed that after being given a reminder and explanation of professional knowledge by pharmacists, the proportion of influenza vaccinations in patients increased.[@CIT0025],[@CIT0046] In another study, the pharmacist's counselling service had a positive effect on patients' access to relevant COPD information.[@CIT0029]

Outcomes {#S0003-S2005}
--------

The impact of outputs on patients can be further summarized as final outcomes, involving patients in clinical (n=6), humanistic (n=1), and economic (n=1) aspects. In terms of the clinical outcomes of pharmacist intervention, the related symptoms of patients with COPD[@CIT0029],[@CIT0036],[@CIT0038],[@CIT0041] the frequency of acute onset,[@CIT0029],[@CIT0031],[@CIT0033] and the hospitalization rate of patients[@CIT0029],[@CIT0032] decreased, but the severity of the onset period did not change significantly.[@CIT0033] Detoni et al and Alton and Farndon, in their reports of patients' health status, proved that intervention by the pharmacist can improve the overall health of patients, through two sets of experimental methods,[@CIT0041],[@CIT0045] but Takemura et al and Tommelein et al did not recognize the positive effect on the patient's health status.[@CIT0031],[@CIT0033] Two other studies showed positive effects of pharmacist services on patients' quality of life, but one of the studies showed no significant positive effects, possibly because of the short intervention time.[@CIT0029],[@CIT0036]

In terms of patients' humanistic outcomes, two related studies revealed that patients' satisfaction with pharmacy services was improved by pharmacists' services.[@CIT0029],[@CIT0047] As for economic outcomes, Wright et al indicated that community pharmacists provided patients with 6-month counselling, lifestyle advice, smoking cessation advice, and referral to physicians, which led to a significant cost reduction in treating COPD in health costs, due to pharmacist intervention.[@CIT0036]

Contextual Factors {#S0003-S2006}
------------------

In the selected literature, the contextual factors affecting the pharmacist's provision of pharmacy services can be summarized for three stakeholders involved in medical services, namely pharmacists, patients, and other medical service providers, as well as three economic factors, namely the facilities, clinic context, and socio-economic factors.

For pharmacists, the most commonly mentioned related contextual factor was that the existing workload of the pharmacist meant that the pharmacist lacked service time[@CIT0028],[@CIT0033],[@CIT0048] and had a work overload problem.[@CIT0048] Studies have also shown that pharmacists were concerned about inadequate service competence, and a lack of knowledge in this area could lead to confusion when serving patients, which is not conducive to pharmacists' providing long-term services.[@CIT0033],[@CIT0048] Some studies have pointed out that pharmacists considered that the control of COPD requires the assistance of many healthcare providers,[@CIT0026],[@CIT0035],[@CIT0040],[@CIT0045],[@CIT0047],[@CIT0048] such as physicians[@CIT0026],[@CIT0040] and nurses,[@CIT0045] in addition to pharmacists; communication between different healthcare providers[@CIT0035] and interdisciplinary collaboration[@CIT0047] also need to receive attention. Contextual factors for patients included that patients may not have enough time to receive services from pharmacists,[@CIT0048] the willingness to pay for pharmacy services, which needs further research,[@CIT0030] possible cognitive function decline in older patients,[@CIT0037] and patients' attitude and lack of COPD awareness.[@CIT0047],[@CIT0048]

At the external environmental level, pharmacists need more economic funding support to provide the impetus to implement interventions;[@CIT0030],[@CIT0033],[@CIT0036],[@CIT0047],[@CIT0048] in particular, financial support from the government would demonstrate its positive role in this process.[@CIT0036],[@CIT0047] If researchers could prove that the cost of pharmaceutical care in COPD reduced health insurance spending, further promotion of this service would be supported by medical insurance departments.[@CIT0034] In addition, if the pharmaceutical service required the intervention of the medical insurance department, the software-related support required for the service and the connection with the medical insurance payment system would also need to be established simultaneously.[@CIT0032],[@CIT0040]

Discussion {#S0004}
==========

This research identified 25 studies from the literature published in the past decade and employed a logic model to display the current research landscape on the professional services provided by community pharmacists in COPD management. As depicted in the model shown in [Figure 2](#F0002){ref-type="fig"}, the influence of external contextual factors on the intervention's ability to produce outputs and outcomes, the interrelationships among interventional components, and the pathways through which interventions produced certain outputs and outcomes (clinical, humanistic, and economic) were clearly illustrated. Unlike most of the previous research, which mainly focused on reporting the pharmacist's interventions and the expected output and/or outcome, this study provided a broader perspective on the relationships among the contextual factors, interventions, outputs, and outcomes, which can be used to inform the development, implementation, and evaluation of community pharmacist services in COPD management.Figure 2Economic, Clinical, and Humanistic Outcomes (ECHO) model of patient outcomes of pharmacists' intervention on COPD management.

Community pharmacists remain some of the most accessible healthcare professionals to address patient needs with appropriate support in many countries around the world.[@CIT0008],[@CIT0018] Their interventions in COPD extend beyond patient-focused management (therapy management and long-term health management) towards population-oriented services (primary prevention and early detection), reflecting pharmacists' increasingly important role in public health. These findings concur with the guidance developed by the FIP on how pharmacists contribute towards overcoming COPD and other non-communicable diseases in the community.[@CIT0010] The primary effect of pharmaceutical services was to optimize the drug treatment for patients: to ensure that patients can use drugs safely and effectively,maximize the effects of drugs in use and minimize adverse drug reactions.[@CIT0041] Long-term follow-up for patients by pharmacists and monitoring of the risk of exacerbations were also expected to improve patient medication behaviours, thereby improving medication compliance and, finally, greatly reducing the further development of COPD.[@CIT0050]

Moreover, based on the current study, there was a general agreement on the practicality and feasibility of community pharmacists' interventions in improving early detection and diagnosis,[@CIT0024],[@CIT0030],[@CIT0035],[@CIT0040],[@CIT0047] supporting smoking cessation,[@CIT0027],[@CIT0030],[@CIT0036],[@CIT0038] ensuring that patients acquire the skills to use inhalator devices appropriately,[@CIT0026],[@CIT0029],[@CIT0031]-[@CIT0034],[@CIT0037],[@CIT0042],[@CIT0044],[@CIT0045],[@CIT0047] and promoting influenza vaccination to population groups at risk of COPD or exacerbations.[@CIT0025],[@CIT0046] However, areas such as collaborating with doctors and other healthcare providers to provide integrative care were under-researched. Optimizing health-related outcomes for COPD patients requires coordinated care from a multidisciplinary healthcare team including pharmacists, doctors, nutritionists, and physiotherapists, as well as patients and caregivers.[@CIT0010] Existing studies on collaborative COPD care models focused mainly on clinical pharmacists.[@CIT0006],[@CIT0051] Considering the importance of continuity of care in improving COPD patient outcomes (including a reduction in all-cause mortality[@CIT0052]), a collaborative care model with guided practice protocols should be developed to integrate community pharmacists into the ongoing therapeutic support for COPD patients and to promote the understanding of and respect for pharmacists' potential to contribute, and most importantly, to guide good practice among pharmacists.[@CIT0005],[@CIT0053]-[@CIT0055]

To expand and consolidate the role of community pharmacists in managing COPD, it is important to demonstrate the added value of pharmacists' interventions on the overall disease management and the clinical outcome of the patients. As shown in [Figure 2](#F0002){ref-type="fig"}, previous research analysed in this study may be divided into two groups: simple intervention, with the impact often measured in terms of output (the grey dotted lines); and multi-intervention study design, to evaluate the impact on patient outcomes (the coloured solid lines). Traditionally, the practice of community pharmacists focused on outputs, which were mainly process or practice focused.[@CIT0056] While outputs remain important performance indicators of pharmacists' intervention, professional services provided by pharmacists should strive to demonstrate their true values, ie the translation from process output into patient outcomes. For instance, direct measurement may be sufficient to demonstrate the effect of pharmacist-led smoking cessation programmes in increasing smoking cessation rates compared with usual care.[@CIT0057] However, more robust studies are needed to demonstrate that the intervention provided by pharmacists could result in positive outcomes on COPD prevention and progression.[@CIT0045] Furthermore, it usually took multiple interventions that worked collectively to contribute to a common set of patient outcomes.[@CIT0029],[@CIT0031]-[@CIT0033],[@CIT0036],[@CIT0038],[@CIT0041],[@CIT0045],[@CIT0047] For instance, Wright et al demonstrated that the support service provided by community pharmacists for COPD patients may include, in addition to smoking cessation support, simultaneous therapy management and long-term care, to enhance medication adherence and increase quitting rates, which can eventually help to improve patients' quality of life, reduce COPD symptoms, and cut costs.[@CIT0036]

The patient outcomes of pharmacists' intervention on COPD management were classified using the ECHO model, as shown in [Figure 2](#F0002){ref-type="fig"}. The ECHO model advocated a balanced and multidimensional assessment of the value of pharmacists' interventions.[@CIT0020] Not surprisingly, the majority of previous research aimed to understand the impact of pharmacists' contribution to COPD management in terms of clinical indicators and outcomes, which were typically more familiar and accepted measures for healthcare providers when evaluating patients' health status. However, the other two constructs of the ECHO model, humanistic and economic outcomes, were tested less frequently, although they have become increasingly critical indicators in evaluation of healthcare in the context of patient-centred care and limited healthcare resources, respectively.

Humanistic outcome is often measured in terms of patient satisfaction with pharmaceutical services.[@CIT0058],[@CIT0059] Patient satisfaction also served as an important determinant of the viability and sustainability of healthcare services, effective use of healthcare resources, likelihood of continuously using healthcare services, adherence to treatment, and resulting in better health outcomes.[@CIT0060],[@CIT0061] However, reports about humanistic outcomes associated with pharmacists' intervention in COPD management remained scarce. The value of pharmacists' intervention should also be measured in economic terms, whether they be direct, indirect, or intangible costs. On the other hand, economic evaluation of clinical pharmacy services has been promoted since the late 1990s[@CIT0062],[@CIT0063] and positive economic benefits as a result of pharmacists' interventions and services have been reported.[@CIT0064] Among the great challenges to improving the quality of healthcare despite limited healthcare resources, economic outcomes are an increasingly substantive focus among healthcare policy-makers, consumers, and payers during their decision-making process with regard to identifying the most cost-effective healthcare interventions and developing reasonable remuneration mechanisms for the professional services provided.[@CIT0065]--[@CIT0067] To be able to achieve a sustainable development of pharmacists' interventions in COPD management, there needs to be a reasonable remuneration system for which economic indicators about the pharmacists' intervention, such as reductions in direct costs, unscheduled hospital days, or total treatment costs, would be highly relevant.[@CIT0068]

A range of contextual factors that may affect community pharmacists' intervention in COPD management were also summarized in this study. This reconfirmed the multifactorial nature of the readiness to make changes and improvements in pharmacy practice. However, few studies have been conducted to test the effect of the contextual factors, despite their being important predictors of pharmacists' performance. In particular, the shift of the pharmacists' focus from patient/disease management to population/disease prevention requires an additional set of knowledge, skills, attitudes, and behaviour. Formal training of the pharmacy workforce to provide appropriate services in COPD management has been shown to be insufficient.[@CIT0010] The change towards patient-centred care has also made apparent the need for competence building to enable the transformation of pharmacist services.[@CIT0069] However, a lack of knowledge regarding COPD management was repeatedly discussed in the literature reviewed in this study as one of the major challenges faced by community pharmacists. Pharmacy education on direct patient care and public health should be reinforced and monitored for its effect on improving pharmacists' practice in COPD management.[@CIT0070] Likewise, other modifiable contextual factors should be considered collectively to formulate a strategy that would help to improve pharmacists' skills and eventually benefit patient outcomes.

This study has some limitations. First, this research is based only on a systematic review of published empirical studies. A future study could collect information from other sources, including key stakeholders' opinions, to enrich or modify the model, especially the contextual factors such as funding (reimbursement for COPD drugs and pharmacy services). Second, this model indicates the causal chains among the components, but has not obtained confirmative results about those chains. Future research is needed to test this by conducting quantitative research, for example through meta-analysis or newly designed experimental studies.

Conclusion {#S0005}
==========

Studies in the literature have proposed and examined different components of professional services provided by community pharmacists for COPD management. However, he relationships among outcomes, comprehensive professional services of community pharmacists, and contextual factors have not been systematically tested. More well-designed, rigorous studies with more sensitive and specific outcome measures need to be conducted to assess the effect of community pharmacy practice for COPD management.
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